Skip to main content

Table 4 The association of anticoagulant drugs with VAF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development Number of Bleeding events (Control)
Crowther et al [74] Placebo-controlled 107 (51) Warfarin
Low-dose
(INR 1.4–1.9)
Post
Time to AVG failure Equivalent risk (199 vs. 83 days, NS) 0
(6)
P = 0.03
Bhomi et al [73] Placebo-controlled 50 (25) Heparin
5000 IU i.v
Peri
Primary patency rates of AVF
(6 weeks)
Equivalent risk (96% vs. 92%, P = 0.46) 0
(12)
P < 0.01
D'Ayala et al [72] Placebo-controlled 115 (58) Heparin
5000 IU i.v
Peri
Primary patency rates of VA
(30 days)
Equivalent risk (84% vs. 86%, P = 0.79) 1
(13)
P = 0.008
  1. VAF vascular access failure, VA vascular access, AVF arteriovenous fistula, AVG arteriovenous graft, NS not significant, Peri peri-operative period, Post post-operative period, i.v intravenous